NCT00610363 - Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Gout

Interventions

BIOLOGICAL

Rilonacept

Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.

OTHER

Placebo (for Rilonacept)

Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.

Trial Locations (34)

11576

Roslyn

11803

Plainview

12206

Albany

16635

Duncansville

19611

West Reading

20902

Wheaton

27612

Raleigh

28112

Monroe

29406

Charleston

29601

Grenville

30338

Dunwoody

32720

DeLand

32804

Orlando

33614

Tampa

33710

St. Petersburg

34471

Ocala

42303

Owensboro

44143

Mayfield Village

45242

Cincinnati

46268

Indianapolis

46601

South Bend

59101

Billings

68114

Omaha

73112

Oklahoma City

75235

Dallas

80910

Colorado Srings

83702

Boise

89502

Reno

90601

Whittier

92108

San Diego

93454

Santa Maria

96814

Honolulu

99204

Spokane

Unknown

Tampa

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY